111, Inc. Announces First Quarter 2026 Unaudited Financial Results
111, Inc. reported first-quarter 2026 unaudited results for the period ended March 31, 2026. Net revenue fell 33.1% YoY to RMB2.4 billion (US$342.4m), mainly tied to an asset-light transition. Marketplace service revenue rose 24.7% YoY. Promotional products revenue grew 70.2% to RMB28.9m; gross profit rose 75.0%. Fulfillment expenses dropped 34.6% to RMB61.2m and improved to 2.6% of revenue.
How this was made
The 30-second read
Why it matters
Q1 shows progress on revenue quality (MP service revenue +24.7% YoY) and operational efficiency (fulfillment expense ratio 2.6% vs 2.7%), but profitability remains negative with net loss and non-GAAP net loss still elevated.
Market read
Traders will likely re-price the stock around the tension between improving unit economics/marketplace growth and continued top-line contraction and losses.
What to watch
Non-GAAP loss worsened versus the prior-year quarter, and gross segment profit fell 35.4% YoY—investors may underweight how much of the cost improvement is offset by weaker gross profit and operating leverage.
Background
111 is transitioning from a transaction-driven pharmaceutical distributor toward a more asset-light, platform-oriented model via divestitures and warehouse partnership arrangements.
Ticker impact
111 reported Q1 2026 results showing revenue decline from an asset-light transition, while marketplace service revenue rose 24.7% YoY and fulfillment expense ratio improved.
Near-term bias likely mixed: investors may focus on improving unit economics (2.6% fulfillment expense ratio) but question sustainability given revenue down 33.1% YoY and larger non-GAAP loss.
The print provides multiple directional signals—revenue down materially, yet marketplace service revenue and promotional products/gross profit up; operating loss and non-GAAP loss remain negative, limiting a clean positive read-through.
Market effects
Highlights a healthcare-distribution/platform model shift toward commission/marketplace economics and AI-enabled operations, which may influence sentiment toward similar China healthcare tech/distribution peers.
Could affect broader China-listed healthcare platform sentiment if investors interpret the asset-light transition as improving scalability despite near-term revenue contraction.
Limited direct global read-across, but contributes to the narrative of platformization and margin discipline in healthcare distribution/marketplaces.
Counterpoint
The revenue decline could be largely transitional (divestitures/fulfillment network changes), and the key signal is whether marketplace service growth and promotional product momentum can offset transaction revenue loss over subsequent quarters.
Key entities
- company111, Inc.
Reported Q1 2026 unaudited financial results and detailed its asset-light transition, marketplace growth, and cost improvements.
- productCravit
Flagship promotional product cited with sales growth from 84,000 to 710,000 boxes YoY.
- executiveJunling Liu
Co-Founder, Chairman, and CEO commenting on the platform/AI-enabled operating model and marketplace momentum.
